What Epitalon (Epithalon) is, what cell, animal and human studies show about benefits and side effects, and what the October 2026 HHS peptide policy changed.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Log your Epithalon protocol in PeptIQ
Turn this Epithalon guide into a living protocol — doses, vials, and history in one place.
Epitalon (also spelled Epithalon) is a synthetic peptide of four amino acids: alanine, glutamic acid, aspartic acid and glycine (AEDG). Russian scientists built it from the amino-acid makeup of epithalamin, an older extract of cattle pineal glands. It is sold online as an anti-aging or "telomere" peptide.
Benefits: promising in cells, unproven in people. Epitalon switched on telomerase and lengthened telomeres in human cell studies. In mice it did not extend average lifespan. Human evidence is limited to small, older studies from one research group, and no adequately powered randomized trial has shown it treats or prevents anything.
Side effects: largely unknown. The small human studies reported none, but FDA says it has no safety information for the proposed route, and long-term safety has never been studied.
Status: not FDA approved. On October 30, 2026, HHS listed Epitalon as one of six peptides that licensed pharmacies may compound for individual prescriptions under strict conditions. That is enforcement discretion, not approval.
This PeptIQ.io guide was updated on November 9, 2026 from PubMed, ClinicalTrials.gov, FDA and HHS documents. It contains no dosing information.
Talk to a licensed clinician before using Epitalon or any product sold as Epitalon.
What Is Epitalon?
Epitalon is a tetrapeptide, a chain of just four amino acids, with the sequence Ala-Glu-Asp-Gly. It was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. A 2025 review describes it as synthesized "based on the amino acids composition of Epithalamin, a bovine pineal gland extract."
That history matters, because two different things travel under similar names:
Epithalamin is a mix of peptides extracted from animal pineal glands. Most of the older long-term human studies used this extract.
Epitalon is one defined synthetic molecule. It is what research vials, compounding pharmacies and the 2026 HHS policy refer to.
A 2026 narrative review by US pain and rehabilitation physicians makes the same point: it calls epithalamin "a chemically distinct pineal-derived polypeptide preparation" and treats those studies only as historical context. When a website cites decades of human data for Epitalon, check which substance the study actually used.
PeptIQ.io / Epitalon / 01
Two names, two different substances.
Epitalon is a four-amino-acid peptide made in a lab. Epithalamin is the older pineal gland extract it was modeled on. Many claims mix the two up.
The original
Epithalamin
A mix of peptides extracted from cattle pineal glands. Used in older Russian studies of elderly people.
↓→
The synthetic peptide
Epitalon
One defined molecule, built from the extract’s amino-acid makeup. The substance in the 2026 HHS policy.
Sequence: Ala-Glu-Asp-Gly (AEDG)
AAlanine
EGlutamic acid
DAspartic acid
GGlycine
Evidence, not marketing.Nov 2026
Sources: Araj et al., Int J Mol Sci 2025 (PubMed 40141333); Jain et al., Int J Mol Sci 2026 (PubMed 42884164); HHS enforcement discretion policy, Appendix B (October 30, 2026). Epitalon is also spelled Epithalon or Epithalone.
How Epitalon Is Supposed to Work
Three ideas drive the interest in Epitalon:
Telomeres. Telomeres are protective caps on the ends of chromosomes that shorten as cells divide. Telomerase is the enzyme that rebuilds them. In a 2003 study, adding Epitalon to human fetal fibroblasts (a type of connective-tissue cell) that normally lack telomerase switched the enzyme on and lengthened telomeres.
The pineal gland and melatonin. The pineal gland makes melatonin, which helps set the sleep-wake cycle and tends to fall with age. Studies from the same group reported that pineal peptides restored night-time melatonin release in old monkeys and older adults.
Gene regulation and oxidative stress. Reviews describe effects on antioxidant enzymes, immune signals and gene expression, mostly in cells and animals. The 2025 review notes it "remains uncertain" whether these are its real mechanisms.
A plausible mechanism is a reason to run trials. It is not evidence that Epitalon slows aging in people.
Epitalon Benefits: What the Evidence Actually Shows
Cell studies: the strongest evidence. Beyond the 2003 fibroblast study, an independent UK group published a 2025 study in Biogerontology that confirmed telomere lengthening in normal human epithelial cells and fibroblasts, through more telomerase. In two breast cancer cell lines, Epitalon also lengthened telomeres, but through a different route called ALT (alternative lengthening of telomeres). That is useful for understanding the biology. It also shows why "lengthens telomeres" is not automatically good news: cancer cells rely on telomere maintenance to keep dividing.
Animal studies: mixed. In a 2003 lifespan study, 54 female mice were treated with Epitalon from young adulthood until death, and 54 got saline. Epitalon did not change average lifespan, food intake or body weight. It did increase the lifespan of the longest-lived 10% by 13.3% and maximum lifespan by 12.3%, reduced chromosome damage in bone marrow cells, and was linked to fewer leukemias, with no change in total tumors. Rat studies reported protection of the retina in an inherited retinal degeneration model (2003).
Human studies: small and old. The human data on Epitalon itself are limited:
Retinitis pigmentosa. A 2002 report said Epitalon produced "a positive clinical effect in 90% of the cases" of degenerative retinal disease. The abstract gives no placebo comparison details, and the result has not been independently repeated.
Melatonin in older adults. A 2007 Russian-language study reported that epithalamin and Epitalon raised night-time melatonin in older people with low pineal function. It did not test sleep quality, disease or survival.
Long-term survival. The frequently cited 2003 study of 266 older adults that reported lower death rates over 6–8 years used epithalamin and thymalin, not Epitalon.
The 2026 review sums it up: human evidence "is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa; no adequately powered randomized trial has established therapeutic efficacy." Its conclusion is that Epitalon is "biologically active but clinically unproven."
PeptIQ.io / Epitalon / 02
Strong in the dish. Thin in people.
Most of the excitement about Epitalon comes from the bottom two rungs. Read it from the top: that is what would tell you it works in humans.
Randomized trials
No adequately powered randomized trial has shown that Epitalon treats or prevents anything.
Missing
Small human studies
Melatonin rhythm in older adults (2007) and a retinitis pigmentosa report (2002). Small, from one research group, not independently repeated.
Thin
Animal studies
Mice: no change in average lifespan, longer life in the oldest survivors, fewer leukemias. Rats: retina protection.
Some signal
Cell studies
Telomerase switched on and telomeres lengthened in human cells (2003, 2025). In cancer cells it also lengthened telomeres, by a different route.
Are any trials running? A ClinicalTrials.gov search on November 9, 2026 returned one record mentioning Epitalon: NCT07888595, an early-phase, single-group study without a control arm that includes Epitalon among several peptides in a topical skin serum and measures "biological age" clocks. It is not a trial of Epitalon on its own, and it will not show whether Epitalon helps people live longer or healthier.
So claims that Epitalon "reverses aging," "extends lifespan" or "fixes sleep" go well beyond the evidence. Even the mouse study did not show a longer average life.
Epitalon Side Effects and Safety
There is no FDA label for Epitalon, so there is no official list of side effects. Here is what is known:
Small human studies reported no side effects. The 2007 melatonin study described the pineal preparations as "having no side effects," and HHS wrote in 2026 that "the limited controlled human exposure reported no side effects." Small, short studies are not designed to catch rare or delayed harms.
FDA flagged immune and purity risks. When it placed Epitalon in Category 2, FDA wrote that compounded Epitalon "may pose risk for immunogenicity" (the body reacting against the peptide) because of possible aggregation and peptide-related impurities, and that it had not found safety information for the proposed route. HHS later said these concerns were "mechanistic rather than based on observed harm."
Long-term and cancer questions are open. The 2026 review lists pharmacokinetic, dose-ranging and long-term safety data as "inadequate," with "oncologic, immunogenicity, product-quality, and regulatory uncertainties" unresolved. The 2025 cancer cell finding is one reason people with a cancer history should raise this with their oncologist.
Product quality is its own risk. A research-use vial has no regulator checking identity, purity, sterility or endotoxins. Under the HHS policy, even pharmacies may only compound Epitalon from a tested, documented source, which tells you how much quality matters.
What about Epitalon half-life? No reliable human pharmacokinetic study gives one. The 2026 review calls the pharmacokinetic data inadequate, so half-life figures quoted on vendor sites are not backed by published human data.
Is Epitalon FDA Approved or Legal in 2026?
No, Epitalon is not FDA approved for any use. Its regulatory status did change several times in 2026:
September 29, 2023 to April 22, 2026: Category 2. FDA placed Epitalon on its list of bulk substances that may present significant safety risks in compounding. FDA's Category 2 page, current as of April 22, 2026, now lists it as nominated but withdrawn.
July 24, 2026: advisory committee. FDA's Pharmacy Compounding Advisory Committee reviewed Epitalon for one nominated use, insomnia. According to HHS, FDA's drug center recommended against listing it and the committee voted in favor. Our post on the advisory vote covers that meeting.
October 30, 2026: HHS Appendix A. HHS published an interim enforcement discretion policy for six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For Epitalon, it covers only injectable forms under the skin or into muscle, "dispensed in intermittent courses," made from a tested ingredient with a valid certificate of analysis. Products must contain a single active ingredient, need a patient-specific prescription and must be labeled "This is a compounded drug product. Not for resale." Pharmacies must report serious adverse events to FDA MedWatch.
PeptIQ.io / Epitalon / 03
Not approved, but no longer off‑limits.
Epitalon's regulatory position has shifted four times since 2023. None of those steps was an FDA approval.
Sep 29, 2023
FDA Category 2
Flagged for possible immune reactions and impurities. No safety data for the proposed route.
Apr 22, 2026
Removed from Category 2
Listed by FDA as nominated but withdrawn. The removal did not approve anything.
Jul 24, 2026
Advisory committee
Reviewed for insomnia. FDA staff recommended against listing; the committee voted in favor.
Oct 30, 2026
HHS Appendix A
One of six peptides pharmacies may compound under strict conditions, injectable only, in intermittent courses.
Next
Rulemaking
FDA still has to decide, through a formal rule, whether Epitalon joins the 503A bulks list.
Evidence, not marketing.Nov 2026
Sources: FDA, Category 2 bulk drug substances page (content current as of April 22, 2026); FDA PCAC meeting notice (July 23–24, 2026); HHS enforcement discretion policy, Appendices A and B (Federal Register 2026-22192, October 30, 2026). Not legal advice.
What the policy does not do: it does not approve Epitalon, it does not confirm any benefit, and it does not cover research-use-only vials sold online. HHS framed it as a way to steer people away from "research-use-only peptides supplied by foreign manufacturers." FDA still has to decide through rulemaking whether Epitalon goes on the permanent 503A bulks list, and HHS says it may revisit the policy if a safety signal appears.
Some telehealth programs now prescribe compounded versions of the other Appendix A peptides. The meds.you portfolio, for example, runs physician-prescribed brand sites for TB-500 and Semax. As of November 9, 2026, none of the portfolio sites we checked listed Epitalon. If you look at any program, ask which pharmacy compounds the product, where the ingredient comes from and what it was tested for.
None of this is legal advice, and state pharmacy rules vary.
Questions to Ask a Clinician
What am I hoping Epitalon will do, and is there a treatment with stronger evidence for that goal, such as for sleep?
Would this be a compounded prescription under the HHS policy or a research-use chemical? Who made it, and can I see the certificate of analysis?
Does my history of cancer, autoimmune disease or allergies change anything?
How would we judge whether it is doing anything, and when would we stop?
Which reactions should make me stop and call you, and how do I report them to FDA MedWatch?
How PeptIQ.io Helps
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks each peptide claim against published research. Use it on posts calling Epitalon a proven telomere or lifespan peptide. The COA checker and the COA reading guide explain what a lab report does and does not prove, which matters for a peptide whose main documented risk is product quality. If you and your clinician agree on a treatment, the PeptIQ app keeps injections, sleep notes and symptoms on one timeline you can share. Community notes live on the Epithalon wiki page.
Talk to a Licensed Clinician
Talk to a licensed clinician before starting Epitalon. For sleep problems, start with the clinician who can rule out sleep apnea, medication effects and other common causes. For aging or longevity goals, a primary care clinician can check the basics with stronger evidence first. Bring the product name, its label and any certificate of analysis, and report suspected reactions to FDA MedWatch.
Frequently Asked Questions
Q: What is Epitalon?
A: Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was modeled on epithalamin, an extract of animal pineal glands, and is studied for effects on telomeres and melatonin. It is not an FDA-approved drug.
Q: What are the benefits of Epitalon?
A: In cell studies it switched on telomerase and lengthened telomeres. In mice it did not extend average lifespan, though the longest-lived animals lived longer. Human evidence is limited to small, older studies on melatonin and retinal disease, and no adequately powered randomized trial has shown a benefit.
Q: What are the side effects of Epitalon?
A: Small human studies reported no side effects, but they were not designed to find rare or long-term harms. FDA has flagged possible immune reactions and impurities, and long-term and cancer-related safety has not been studied.
Q: Is Epitalon FDA approved?
A: No. Since October 30, 2026, it is one of six peptides in an HHS interim policy that lets licensed pharmacies compound it for individual prescriptions under strict conditions. That is enforcement discretion, not approval, and it does not cover research-use vials.
Q: Does Epitalon really lengthen telomeres?
A: In human cells grown in a lab, yes, in studies from 2003 and 2025. No study has shown that it lengthens telomeres in people in a way that improves health or lifespan. In cancer cell lines it also lengthened telomeres, through a different route.
Q: Is Epitalon the same as epithalamin?
A: No. Epithalamin is a mix of pineal gland peptides. Epitalon is one synthetic molecule based on it. Many long-term human studies cited online, including a study reporting lower death rates in older adults, used epithalamin rather than Epitalon.
Jain A, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. Int J Mol Sci. 2026. PubMed 42884164
Araj SK, et al. Overview of Epitalon, highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025. PubMed 40141333
Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003. PubMed 12937682
Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PubMed 40908429
Anisimov VN, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003. PubMed 14501183
Khavinson VKh, et al. Retinoprotective effect of Epithalon in Campbell rats of various ages. Bull Exp Biol Med. 2003. PubMed 12910293
Khavinson V, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002. PubMed 12195242
Korkushko OV, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. 2007. PubMed 17969590
Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003. PubMed 14523363
ClinicalTrials.gov: search for Epitalon, Epithalon and epithalamin, and NCT07888595. Checked November 9, 2026.
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.